Abiogen licenses RFB4 antibody from Cancer tumor Research Technology Cancer Research Technology Limited , the oncology-focused advancement and commercialisation company, announces it has agreed a special worldwide licence with Abiogen Pharma S today.p.A. . The contract supersedes a prior licence with Abiogen and will enable Abiogen to keep to utilize the RFB4 antibody, in conjunction with key technology from the University of Texas Southwestern INFIRMARY at Dallas, to build up its pipeline therapeutics.And the answers aren’t as basic as you’ll think. What about a factory employee in Detroit or a fresh mother in Berlin? In the current hyperconnected world that is pulling us jointly in so many ways, how do our cultural differences, existence personalities and experiences influence what this means to live a full life? Early in this quest we’re seeing preliminary trends, like the role health plays in a full life in Shanghai and the importance of family in NY. We’ll need to see if that is confirmed as we go global with our research. The one thing that is becoming apparent is merely how personal it gets when we speak to people about lifestyle.